On Mar. 28, 2017, Genentech drug Ocrevus (ocrelizumab) was approved by the U.S. Food and Drug Administration (FDA) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

The majority of people with MS have a relapsing form or primary progressive MS at diagnosis.